Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-04 / J Clin Oncol 37, 2019 (suppl; abstr e21024)A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2019-05-29 / Front Oncol 2019;9:436Melanoma vaccines: clinical status and immune endpoints
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-18 / J Immunol Res 2018;2018:3982942Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de